Before the availability of pegylated interferons (PEG-IFNs), interferon-α, with or without ribavirin, was the preferred first-line treatment for HCV-infected individuals; HBV-infected individuals ...

Results from the pegylated versus standard interferon- -2b/ribavirin combination study raise a number of issues concerning optimum dosage and duration of treatment with the pegylated formulation.

Introduction How Serious is the Problem? Treatment Options Increasing Pegylation Increases Half-Life... References ...

Most of these are antiviral drugs that directly stop hepatitis B from reproducing. Hepatitis B treatment may also include pegylated interferon, which stimulates the body's immune response against the ...

They are well tolerated and treatment usually lasts just three months. In comparison, the old standard of care – pegylated interferon alfa (Pegasys or PegIntron) plus ribavirin – required weekly ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) is poised to present significant findings on imdusiran, its RNAi therapeutic, ...

Hepatitis C virus (HCV) is the major cause of liver disease worldwide and a potential source of high morbidity and mortality in the future. The World Health Organization estimates that ...

GSK is conducting trials of bepirovirsen with other therapeutics, with the aim of increasing functional cure rates, including a phase 2b trial in combination with pegylated interferon and a phase ...

and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental immunotherapies. GSK licensed the drug from longstanding ...

Hepatitis just means any disease that causes inflammation of the liver. It can be caused by a virus or a noninfectious cause.

Regular Abstracts Accepted as Poster Presentations Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...